Enzo Biochem — Proxy Contest (December 2020)
30 slides from Enzo Biochem's proxy contest presentation, Dec 30, 2020
Slide 1: Enzo Biochem, Inc. Immediate Change is Warranted
December 2020 FINDING VALUE THROUGH OUT OF FAVOR, OVERLOOKED OR MISUNDERSTOOD SECURITIES ENZO BIOCHEM, INC. Immediate Change is Warranted Shareholder Presentation
Slide 2: Disclaimers
2 Disclaimers Important Information Concerning the Participants in a Proxy Solicitation : Roumell Asset Management, LLC, Matthew M . Loar, James C . Roumell and Edward Terino (collectively, "Roumell" or "we"), have filed with the Securities and Exchange Commission (the "SEC") a definitive proxy stat
Slide 3: Table of Contents
3 Table of Contents Executive Summary Enzo Biochem , Inc. 4 Roumell Asset Management, LLC 5 Why Immediate Change is Warranted 6 Our History with Enzo 7 Enzo’s Board has Perpetual: Decades of Shareholder Destruction 9 Dismal Shareholder Returns 10 Failed Corporate Governance 11 Poor Returns on Assets
Slide 4: Executive Summary: Enzo Biochem, Inc.
4 Executive Summary Enzo Biochem , Inc. Enzo runs clinical labs in the Northeast region, develops platforms and reagents for use in its own labs and for resale, and operates a therapeutics division Wholly - owned operating companies : 1 . Enzo Clinical Labs, Inc . (“Enzo Labs”) • Segment includes a
Slide 5: Executive Summary: Roumell Asset Management, LLC
5 Executive Summary Roumell Asset Management, LLC Roumell Asset Management, LLC (“RAM”) pursues long - term capital growth through opportunistic value investing . We seek to own a non - diversified portfolio of deeply researched, conservatively financed securities that are out of favor, overlooked o
Slide 6: Why Immediate Change is Warranted
6 Executive Summary Why Immediate Change is Warranted Obvious wrongs should be righted with obvious solutions • RAM is one of Enzo’s largest shareholders, owning 5 . 8 % of the Company’s outstanding Common Stock • We are seeking to elect two highly qualified independent directors to represent shareh
Slide 7: Our History with Enzo
7 Our History with Enzo • In 2018 , RAM began purchasing shares of ENZ based on the following : • Enviable Clinical Lab footprint in the New York tri - state area • Life Sciences unit creating proprietary products • Promising Therapeutics division • Patent - enforcement litigation optionality • In A
Slide 8: Our History with Enzo (continued)
8 Our History with Enzo (continued) • Our belief that Harbert would likely run an additional proxy campaign to dislodge Dr . Rabbani (which turned out to be incorrect) and the Company’s success in receiving Emergency Use Authorization (EUA) for its Proprietary Test System for Detection of Coronaviru
Slide 9: Enzo's Board has Perpetual Decades of Shareholder Destruction
9 • Dismal stock performance • Severe underperformance compared to Enzo’s peers and relevant indices • Failed corporate governance • Complex web of related parties and self - dealings • No substantial improvements over the years despite being the subject of prior proxy fights • Poor capital allocati
Slide 10: Dismal Shareholder Returns
10 Enzo’s Board has Perpetual Dismal Shareholder Returns 20 year 10 year 5 year 1 year Enzo Biochem (ENZ) -93.1% -53.0% -56.2% -25.4% Laboratory Corporation of America (LH) 483.9% 147.3% 63.8% 15.2% Quest Diagnostics (DGX)* 352.8% 151.7% 81.5% 16.5% Invesco S&P SmallCap Health Care ETF (PSCH) N/A 49
Slide 11: Failed Corporate Governance
11 • Outdated governance structure • Combined CEO and Chairman role • Classified Board • Conflicts of interest • CEO/Chairman tenured for 44 years • No shareholder right to call a special meeting ________________________________________________________________________________________________________
Slide 12: Poor Returns on Assets, Equity and Capital
12 Fiscal Year Return on Assets Return on Equity Return on Invested Capital 2011 -11.5% -14.0% -8.9% 2012 -44.0% -57.0% -46.9% 2013 -28.5% -43.8% -29.6% 2014 -16.2% -28.1% -17.1% 2015 -3.4% -5.7% 1.6% 2016 50.3% 68.5% 67.3% 2017 -2.3% -2.8% -0.2% 2018 -9.9% -12.1% -12.4% 2019 2.4% 3.0% 2.1% 2020 -25
Slide 13: Outsized Executive Compensation
13 As noted in Institutional Shareholder Services, Inc . ’s (“ISS”) Proxy Analysis for the 2020 Annual Meeting, “[t]he compensation committee demonstrated poor responsiveness following significant shareholder opposition to last year's say - on - pay proposal . Given that no compensation committee me
Slide 14: Unchecked Related Party Transactions
14 • Enzo Labs has leased a facility in Farmingdale, New York from Pari Management Corporation (“Pari”) since 1989 • Pari is owned equally by Dr . Rabbani, Mr . Weiner (and his wife), and former officer and director Shahram Rabbani (co - founder and Dr . Rabbani’s brother) • In fiscal year 2019 , En
Slide 15: A History of Broken Promises
15 A History of Broken Promises • Beginning on the March 12 th, 2018 investor call, Mr . Weiner suggested that monetizing the Company’s therapeutic assets is imminent . On the March 12 th, 2018 call, Mr . Weiner teasingly said, “I can’t say too much,” signaling that the Company was close to monetizi
Slide 16: Enzo is Trying to Fool Shareholders by Selectively Quoting Roumell
16 Enzo is Trying to Fool Shareholders by Selectively Quoting Roumell Enzo wrote : In fact, Roumell complimented Dr . Rabbani and new CFO David Bench - On October 28 , 2020 , he expressed his “satisfaction with the Company’s recent initiatives” and noted the Company’s hiring of a new Chief Financial
Slide 17: Immediate Change is Warranted
17 Immediate Change is Warranted • Enzo spent $ 4 . 1 million of shareholder resources in its campaign against Harbert, 7 % of the Company’s cash balance as of October 31 , 2019 , in a failed bid to disallow shareholder directed board representation • In its report published in connection with the 2
Slide 18: A Perennial "Science Project"
18 A Perennial “Science Project” • Number of patents has nearly doubled from 245 in 2015 to 475 in 2020 • Over the past several years, Enzo has won over $ 125 million in legal settlements for patent infringement • Future awards appear to be highly unlikely as the Supreme Court denied Enzo’s petition
Slide 19: A Perennial "Science Project" (chart)
19 A Perennial “Science Project” Patents are way up, but stock price is still down…clearly, patents, Ph.D.’s and M.D.’s have not translated into shareholder wealth creation Shareholders are not interested in financing long - term science projects 0 50 100 150 200 250 300 350 400 450 500 07/31/15 07/
Slide 20: Former Enzo Directors
20 Former Enzo Directors Enzo has never suffered from a lack of Ph . D . and/or M . D . Directors • Drs . Tagliaferri and Walters are highly trained professionals in their respective fields, but such respective talent has never resulted in value creation for ENZ shareholders • On December 28 , 2020
Slide 21: Our Nominations for the Board
21 Our Nominations for the Board • We have nominated Matthew M . Loar and Edward Terino to the Board at the 2020 Annual Meeting • Each is a seasoned public company executive with significant public board experience • Mr . Terino has been placed on a number of public company boards as a result of sha
Slide 22: Highly-Qualified Candidates: Edward Terino
22 Highly - Qualified Candidates EDWARD TERINO High energy, results - oriented leader with over 40 years of international Board and C - level experience in many different industries, including educational publishing, enterprise software, healthcare, financial services, maritime transportation, and t
Slide 23: Highly-Qualified Candidates: Matthew M. Loar
23 Highly - Qualified Candidates MATTHEW M . LOAR CPA with over ten years of experience as CFO for both public and private companies in the biopharmaceutical industry . Matthew M . Loar, age 57 , is an independent financial consultant to public and private companies in the health care industry, and
Slide 24: Nominees' Top Priorities if Chosen to Serve on the Board
24 Nominees’ Top Priorities if Chosen to Serve on the Board • Increase shareholder value through understanding the Company's business strategy and corresponding intermediate (three - year) financial plan • Identify and evaluate strategic alliance and partnership opportunities • Improve corporate gov
Slide 25: Addendum A
25 Addendum A In May 2019, RAM sought to constructively engage with ENZ and allay any concerns ENZ might have about RAM’s investment strategy and yet was still rebuffed by ENZ , which was one of the reasons RAM sold its shares of Common Stock later that year Elazar and Barry - Thank you for taking t
Slide 26: Addendum B
26 Addendum B Comments by Barry Weiner on Conference Calls and in Press Releases Press Release dated December 7 , 2015 – Results for the First Fiscal Quarter ended October 31 , 2015 1 Comments by Barry Weiner : “ … .. we believe we can address the challenges facing the molecular diagnostics industry
Slide 27: Addendum B (continued)
27 Addendum B (continued) Press Release dated September 27 , 2017 – Results for the Fourth Quarter and Fiscal Year ended July 31 , 2017 3 Comments by Barry Weiner : “Our position as an innovative provider of low cost but highly versatile women’s health diagnostics has likewise resulted in expanding
Slide 28: Addendum B (continued)
28 Addendum B (continued) Earnings Release Call held on June 12 , 2018 – Results for the Third Fiscal Quarter ended April 30 , 2018 5 Comments by Barry Weiner : “We have had an area of activity in the therapeutic area for quite a while . It has been quietly pursued . We’ve kept some very interesting
Slide 29: Addendum B (continued)
29 Addendum B (continued) Earnings Release Call held on March 12 , 2019 – Results for the Second Fiscal Quarter and First Half ended January 31 , 2019 8 Comments by Barry Weiner : “Enzo has expanded on marketing and sales activities to address the market opportunities which include a broad range of
Slide 30: Addendum B (continued)
30 Addendum B (continued) Earnings Release Call held on October 15 , 2019 – Results for the Fourth Quarter and Fiscal Year ended July 31 , 2019 10 Comments by Barry Weiner : “One important note related to our strategic activities . As we noted in a release and so has retained Lazard to Assist in Str